Hi Everyone!

I’m wondering how you all approach the treatment of Stage IIIA patients and do you treat them with adjuvant nivolumab? I’ve found this to be a bit of a difficult area in discussion with patients, in that the study that led to the approval of nivolumab did not include stage IIIA patients, but the FDA approval was a blanket approval for all stage III patients and was not specific. Unfortunately, we will not gain any insight from Checkmate 915 either as stage IIIA patients are excluded from the trial. Looking forward to people’s thoughts.